This comprehensive update examines major antitrust enforcement actions and regulatory developments across seven jurisdictions during mid-2026, including landmark U.S. litigation over pharmaceutical pricing, DOJ investigations into agricultural markets and healthcare contracting, and significant European Commission proceedings involving vaccine disparagement and foreign subsidies. The report also covers enforcement activities by competition authorities in Mexico, Poland, Italy, the Netherlands, and Germany's
GlobalAntitrust/Competition Law
In This Issue1
United States | Mexico | Poland | Italy | The Netherlands | European Union | Germany
United States
A. U.S. Litigation
1. Amgen v. Mizner, Case No. 1:25-CV-03452 (D. Colo. July 1, 2026).
On July 1, 2026, the Honorable Judge Daniel D. Domenico entered an order temporarily blocking enforcement of the State of Colorado’s price cap on arthritis medication. Amgen, Inc., the manufacturer of the arthritis drug Enbrel, brought the lawsuit, alleging that the price cap violated federal protections for patented medications. Though Judge Domenico acknowledged that Colorado had legitimate interests in protecting patients from high drug prices, he nevertheless held that the law violated the “bargain struck by Congress” in allowing holders of drug patents to charge supracompetitive prices for their medications, so long as the patents are enforceable.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
View source